Fig. 3From: Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case reportCT scan before and after the dual combination therapy. a Recurrent pelvic tumors (yellow arrow) were noticed in May 2019 (upper panel: axial view; lower panel: sagittal view). b Significant regression of recurrent pelvic tumors was found in November 2019 (upper panel: axial view; lower panel: sagittal view)Back to article page